Understanding survival factors in cholangiocarcinoma patients
Prognostic Factors for Survival in Patients With Cholangiocarcinoma
This study looks at how different treatments affect survival rates in people with cholangiocarcinoma to help doctors make better decisions for their patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Sex | All |
| Sponsor | Rigshospitalet, Denmark Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Copenhagen) |
| Trial ID | NCT06369480 on ClinicalTrials.gov |
What this trial studies
This observational study aims to analyze survival rates in patients diagnosed with cholangiocarcinoma (CCA) based on various treatment approaches over a seven-year period across four hospitals in Denmark. By examining the medical records of patients, the study will identify prognostic factors associated with poor survival outcomes. The findings are expected to enhance clinical decision-making and improve patient care in managing CCA.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with cholangiocarcinoma confirmed by a multidisciplinary team in Denmark between 2013 and 2020.
Not a fit: Patients who have undergone multiple interventions or whose cholangiocarcinoma diagnosis was later canceled will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide critical insights that lead to improved treatment strategies and better survival rates for cholangiocarcinoma patients.
How similar studies have performed: While there have been studies on cholangiocarcinoma, this specific approach focusing on survival factors based on treatment modalities is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients' eligibility for this study is contingent on a diagnosis of CCA confirmed by the MDT from Aalborg Universitetshospital, Aarhus Universitetshospital, Odense Universitetshospital, and Rigshospitalet in Denmark from 2013 to 2020. Exclusion Criteria: * We will exclude from the analysis all records with more than one interventions. Additionally, all patients whose cholangiocarcinoma diagnosis was canceled following the MDT meeting will be also excluded, as well those with inconsistent data regarding date of reference to the MDT.
Where this trial is running
Copenhagen
- Rigshospitalet — Copenhagen, Denmark (Recruiting)
Study contacts
- Principal investigator: Hans-Christian Pommergaard, M.D./Ph.D. — Rigshospitalet, Denmark
- Study coordinator: Hans-Christian Pommergaard, M.D./Ph.D
- Email: hans-christian.pommergaard@regionh.dk
- Phone: 35458519
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.